No. Where possible we are issuing only ONE SINGLE REDCap login per site.
The login details can be shared with all members of your team who will be responsible for uploading patient data. We encourage teamwork to identify patients and upload data, to increase data accuracy.
If you believe your hospital would benefit from having more than one account (e.g. large hospital with multiple teams collecting data separately), please email us ([email protected]) and we issue more than one login if appropriate.
Yes – to help sub-teams within hospitals to navigate faster to only relevant records we have created a speciality-specific dashboard on REDCap. Here you can select the sub-study in which you are participating and see only those patient records.
A short tutorial video on how to navigate the dashboard can be found at:
You should include patients diagnosed with SARS-CoV-2 infection within 7 days before or 30 days after surgery (via lab test, computed tomography scan or clinical diagnosis in the absence of the previous). Patients being diagnosed outside of this time-window should be excluded from CovidSurg cohort study.
The index operation should be taken as the first operation they had after SARS-CoV-2 diagnosis (this operation should be within 7 days of SARS-CoV-2 diagnosis in order for the patient to be eligible for inclusion).
Yes – you can retrospectively collect data about patients who previously underwent surgery and were diagnosed with SARS-CoV-2 infection within 7 days before or 30 days after surgery (via lab test, computed tomography scan or clinical diagnosis in the absence of the previous).
Primary endpoint is 30-day mortality, including in-hospital or out of hospital follow-up. However, we don’t expect any additional follow-up. So, data can be completed using the information available at the hospital at 30 days (accepting that this may miss some morbidity /mortality in the community).
Investigators can enrol patients with confirmed diagnoses of Colorectal, Oesophagogastric, Head & Neck, Lung, Hepatopancreatobiliary, Urological, Neurological, Gynaecological, Breast cancers and soft-tissue or Bone Sarcoma.